Kenya has become the first country to introduce a new Child-friendly Tuberculosis medicines. The new products are expected to improve treatment and child survival from TB
TB Alliance announced the launch of new medicines for childhood tuberculosis (TB) in Kenya last Tuesday, marking the first national roll out of these products. Released in partnership with the Kenya Ministry of Health, UNITAID, and others, these medicines are easier for caregivers to give and for children to take, and are expected to help improve treatment and child survival from TB.
“Kenya is playing a leading role in the fight against childhood TB by being the first to introduce improved TB medicines for children,” explained Kenya’s Cabinet Secretary for Health Dr Cleopa Mailu. “Now, with the appropriate treatments, we can make rapid progress in finding and treating children with TB so we can achieve a TB free generation.”
Tuberculosis still remains a major killer of children. According to the World Health Organization (WHO), at least 1 million children suffer from TB each year and 140,000 children die of this preventable, treatable, and curable disease. In 2015, Kenya reported nearly 7,000 cases of TB in infants and children, with those under age five at greatest risk of having severe forms of TB and dying from the disease.
Previously, caregivers had to cut or crush multiple, bitter-tasting pills in an attempt to achieve the right doses for children. This made the six-month treatment journey difficult for children and their families, contributing to treatment failure and death from the disease.
The treatments now being introduced are the first to meet WHO guidelines for childhood TB treatment. They are not new drugs but improved formulations that come in the correct doses, require fewer pills, are flavored and dissolve in water.
“These new treatments will not have an impact until they reach the children that need them,” said Dr. Cherise Scott, Director of Pediatric Programs for TB Alliance. “We are proud to partner with the Government of Kenya, the first of many countries, as they work to translate the potential of these medicines into lives saved.”
“No child should die of TB, yet for too long, we have not had the medicines to mount a sustainable response against childhood TB,” said Mr. Robert Matiru, Director of Operations for UNITAID. “UNITAID’s investment in addressing this problem should help equip countries, health care workers, and families with the tools they need to rise to the challenge.”
Starting October 1, 2016, all children in Kenya initiated on TB treatment will be given the improved formulation. “Childhood TB is a problem that can be solved when we choose to act,” said Dr. Enos Masini, Head of Kenya’s National Tuberculosis, Leprosy, and Lung Disease Program.
Children often get TB from infected persons in their environment. This can be at home, at school or in any other place where children spend their time. Children should be taken to the nearest health facility to receive a TB diagnosis if they have a cough, fever, night sweats, reduced playfulness, or if they fail to gain weight. If any member of the household is diagnosed with TB, all other household members should be tested for TB, especially children.
TB testing and treatment is free at all public health facilities in Kenya.
The development of the medicines was overseen by TB Alliance, an international not-for-profit organization, and was funded by UNITAID and other partners.
Kobby Blay is the chief health editor at Ghanahealthnest.com. A professional practicing nurse with specialty in mental health and focus for health communications, public health, medical/documentary photography, ICT and systems perspective for health improvement.